8x1200 Combination Cable Lock 8x1200 Combination Cable Lock WENZHOU JINJIAN SMART LOCK CO.,LTD , https://www.jinjianlocks.com
Handa Pharmaceutical is a small R&D enterprise in the United States and specializes in slow-release preparations and development of challenging generics. The so-called generic drugs that challenge patents refer to the P4 application channel regulated by the US FDA. Before the expired patents for generic drugs are expired, the same products can be created through technology innovation without infringing patents, thus breaking the patent drug market. Monopoly reduces the economic burden on patients. Fosun Pharma invested in Handa Pharmaceuticals in 2009 and strongly supported its development of generic drugs that target challenging patents in Europe and the United States.
According to Cui Zhiping, Vice President of Fosun Pharma and General Manager of the International Department, generic drugs, especially challenging patent generic drugs, have very broad market prospects. The profitability of the first generic products such as quetiapine is considerable.
A few days ago, Handa Pharmaceuticals, a shareholder of Fosun Pharmaceutical, received an official notice from the US FDA that its imitation of a large-scale sustained-release quetiapine has received pre-approval (tentative approval). This is the first product in China's pharmaceutical companies affiliated company to receive approval.